South Korea · Delayed Price · Currency is KRW BioNote Statistics
Total Valuation
BioNote has a market cap or net worth of KRW 535.19 billion. The enterprise value is 151.00 billion.
| Market Cap | 535.19B |
| Enterprise Value | 151.00B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | Mar 28, 2025 |
Share Statistics
BioNote has 101.36 million shares outstanding. The number of shares has decreased by -0.29% in one year.
| Current Share Class | 101.36M |
| Shares Outstanding | 101.36M |
| Shares Change (YoY) | -0.29% |
| Shares Change (QoQ) | -0.19% |
| Owned by Insiders (%) | 58.09% |
| Owned by Institutions (%) | 0.17% |
| Float | 14.54M |
Valuation Ratios
The trailing PE ratio is 12.69.
| PE Ratio | 12.69 |
| Forward PE | n/a |
| PS Ratio | 5.05 |
| PB Ratio | 0.33 |
| P/TBV Ratio | 0.33 |
| P/FCF Ratio | 15.59 |
| P/OCF Ratio | 11.26 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.60, with an EV/FCF ratio of 4.40.
| EV / Earnings | 3.56 |
| EV / Sales | 1.43 |
| EV / EBITDA | 3.60 |
| EV / EBIT | 4.49 |
| EV / FCF | 4.40 |
Financial Position
The company has a current ratio of 11.56, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.56 |
| Quick Ratio | 10.69 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.18 |
| Debt / FCF | 0.11 |
| Interest Coverage | 52.02 |
Financial Efficiency
Return on equity (ROE) is 2.66% and return on invested capital (ROIC) is 0.53%.
| Return on Equity (ROE) | 2.66% |
| Return on Assets (ROA) | 0.51% |
| Return on Invested Capital (ROIC) | 0.53% |
| Return on Capital Employed (ROCE) | 0.81% |
| Revenue Per Employee | 355.43M |
| Profits Per Employee | 142.20M |
| Employee Count | 298 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 1.99 |
Taxes
In the past 12 months, BioNote has paid 14.01 billion in taxes.
| Income Tax | 14.01B |
| Effective Tax Rate | 24.85% |
Stock Price Statistics
The stock price has increased by +28.12% in the last 52 weeks. The beta is 1.05, so BioNote's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +28.12% |
| 50-Day Moving Average | 5,041.20 |
| 200-Day Moving Average | 4,800.10 |
| Relative Strength Index (RSI) | 56.29 |
| Average Volume (20 Days) | 69,970 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioNote had revenue of KRW 105.92 billion and earned 42.38 billion in profits. Earnings per share was 416.22.
| Revenue | 105.92B |
| Gross Profit | 53.53B |
| Operating Income | 13.47B |
| Pretax Income | 56.39B |
| Net Income | 42.38B |
| EBITDA | 21.75B |
| EBIT | 13.47B |
| Earnings Per Share (EPS) | 416.22 |
Balance Sheet
The company has 388.06 billion in cash and 3.87 billion in debt, giving a net cash position of 384.19 billion or 3,790.28 per share.
| Cash & Cash Equivalents | 388.06B |
| Total Debt | 3.87B |
| Net Cash | 384.19B |
| Net Cash Per Share | 3,790.28 |
| Equity (Book Value) | 1.62T |
| Book Value Per Share | 15,990.55 |
| Working Capital | 422.63B |
Cash Flow
In the last 12 months, operating cash flow was 47.51 billion and capital expenditures -13.19 billion, giving a free cash flow of 34.32 billion.
| Operating Cash Flow | 47.51B |
| Capital Expenditures | -13.19B |
| Free Cash Flow | 34.32B |
| FCF Per Share | 338.64 |
Margins
Gross margin is 50.54%, with operating and profit margins of 12.72% and 40.01%.
| Gross Margin | 50.54% |
| Operating Margin | 12.72% |
| Pretax Margin | 53.24% |
| Profit Margin | 40.01% |
| EBITDA Margin | 20.54% |
| EBIT Margin | 12.72% |
| FCF Margin | 32.41% |
Dividends & Yields
This stock pays an annual dividend of 200.00, which amounts to a dividend yield of 3.77%.
| Dividend Per Share | 200.00 |
| Dividend Yield | 3.77% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 48.17% |
| Buyback Yield | 0.29% |
| Shareholder Yield | 4.07% |
| Earnings Yield | 7.92% |
| FCF Yield | 6.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNote has an Altman Z-Score of 5.06 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.06 |
| Piotroski F-Score | 6 |